Perspective Therapeutics Inc. (CATX) Live Share Price, Invest From India

Perspective Therapeutics Inc. Stock Performance

as on April 21, 2026 at 5:07 am IST

Day's Low
Day's High
$4.31
Day's Price Range
$4.66
$4.64
7.11%
Downside
0.43%
Upside
52 Week's Low
52 Week's High
$1.86
52-Week Price Range
$6.16
$4.64
59.91%
Downside
32.76%
Upside

Perspective Therapeutics Inc. share price movements today

Previous Close: $4.20
Open: $4.58
Volume: 1.6M
Day's Low - High: $4.31 - $4.66
52 Week Low - High: $1.86 - $6.16

Perspective Therapeutics Inc. Historical Returns

1 Month Return: -5.62 %
3 Month Return: + 72.84 %
1 Year Return: + 116.49 %
3 Year Return: -39.22 %
5 Year Return: 0 %

Perspective Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Perspective Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$478.9M

EPS (TTM)

-1.1882

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-110.3M

Revenue (TTM)

884.0K

Profit Margin

0.00%

Return On Equity TTM

-41.65%

Perspective Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Perspective Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Perspective Therapeutics Inc.	BUY	$478.9M	NA	NA	0.00%
Boston Scientific Corp	BUY	$95.5B	56.16%	33.11	14.44%
Stryker Corporation	BUY	$131.5B	32.85%	40.82	12.92%
Medtronic PLC	BUY	$110.7B	-32.81%	24.08	13.00%
Edwards Lifesciences Corp	BUY	$47.0B	-9.64%	44.75	17.69%

See all

Stock Returns calculator for Perspective Therapeutics Inc. Stock including INR - Dollar returns

The Perspective Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Perspective Therapeutics Inc. investment value today

Current value as on today

₹2,61,433

Returns

₹1,61,433

(+161.43%)

Returns from Perspective Therapeutics Inc. Stock

₹1,39,175 (+139.18%)

Dollar Impact

₹22,258 (+22.26%)

Analyst Recommendation on Perspective Therapeutics Inc. Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Perspective Therapeutics Inc.. Average target price of $13

Perspective Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Perspective Therapeutics Inc..

What analysts predicted

64.31%UPSIDE

Target Price

$13

Current Price

$4.64

Analyzed by

8 Analysts

Target

$13.00

Perspective Therapeutics Inc. target price $13, a slight upside of 64.31% compared to current price of $4.64. According to 8 analysts rating.

Perspective Therapeutics Inc. Stock’s Investor Sentiment and Interest

Search interest for Perspective Therapeutics Inc. Stock has decreased by -57% in the last 30 days, reflecting a downward trend in search activity.

Time period: March 21, 2026 to April 20, 2026

Change:-57% versus previous 30 day period

Perspective Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	1	0	-	-	-	-	0	0	0	-
Gross Profit	0	0	-	-	-	-	0	0	0	-
Operating Income	-10	-7	-13	-14	-18	-44	-21	-24	-27	82
EBITDA	-9	-8	-11	-10	-14	-41	-17	-21	-25	1
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	1
Income Before Tax	-10	-8	-11	-11	-15	-42	-18	-21	-25	-37
Income Tax Expense	0	7	-	0	-	-2	-	-2	-	0
Net Income	-10	-24	-12	-11	-15	-40	-18	-21	-25	-37
Net Profit Margin	-542.48%	-7321.96%	0.00%	0.00%	0.00%	0.00%	-5314.91%	-7408.62%	-12425.36%	0.00%

Perspective Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Jun 2020	Dec 2020	Jun 2021	Dec 2021	Jun 2022	Dec 2022	Jun 2023	Dec 2023	Dec 2024	Dec 2025
Total Revenue	9	10	10	10	10	7	7	1	-	-
Gross Profit	5	5	5	4	4	1	1	1	-	-
Operating Income	-3	-3	-3	-7	-7	-15	-15	-40	10	9
EBITDA	-3	-3	-3	-	-7	-14	-14	-39	10	9
Interest Expense	0	-	0	-	0	0	-	0	0	0
Depreciation	0	0	0	0	0	-	-	0	2	3
Income Before Tax	-3	-3	-3	-7	-7	-14	-14	-40	-81	-103
Income Tax Expense	0	0	0	-	0	0	-	-2	-2	0
Net Income	-3	-3	-3	-7	-7	-14	-14	-46	-79	-103
Net Profit Margin	-33.77%	-31.71%	-31.71%	-67.36%	-66.26%	-206.50%	-206.50%	-3243.24%	0.00%	0.00%

Perspective Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-24	-12	-11	-15	-40	-18	6	-25	-71
Operating Cash Flow	-9	13	-8	3	-26	-21	-19	-16	-16
Investing Cash Flow	0	-47	-3	-29	-138	-5	4	13	33
Financing Cash Flow	0	166	122	0	0	9	0	0	-18
Change in Cash	-8	142	109	-25	-164	-17	-15	-2	3

Perspective Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Jun 2021	Dec 2021	Jun 2022	Dec 2022	Jun 2023	Dec 2023	Dec 2024	Dec 2025
Net Income	-3	-3	-7	-7	-14	-14	-46	-79	-103
Operating Cash Flow	-2	-2	-7	-7	-12	-12	-36	-18	-82
Investing Cash Flow	0	0	-	0	-57	-	24	-218	41
Financing Cash Flow	64	64	0	0	0	0	0	289	10
Change in Cash	61	61	-7	-7	0	0	-46	52	-30

Insights on Perspective Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, CATX has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 3 months, CATX stock has moved up by 72.8%
NO EFFECT
Against Peers
In the last 3 years, Perspective Therapeutics Inc. has experienced a drawdown of -39.2%, however Boston Scientific Corp. resisted the overall trend and outperformed by 33.7%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 342.0K → 209.0K (in $), with an average decrease of 21.6% per quarter
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 4 quarters, -18.17M → -37.49M (in $), with an average decrease of 27.8% per quarter

About Perspective Therapeutics Inc.

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Organisation	Perspective Therapeutics Inc.
Headquarters	2401 Elliott Avenue, Seattle, WA, United States, 98121
Industry	Medical Devices
CEO	Mr. Johan M. Spoor
E-voting on shares	Click here to vote

Key Management of Perspective Therapeutics Inc.

Name	Title
Dr. Markus Puhlmann M.B.A., M.D.	Chief Medical Officer
Mr. Jonathan R. Hunt	Chief Accounting Officer
Dr. Michael K. Schultz Ph.D.	Chief Science Officer
Mr. Amos Hedt BA, PGradDip	Chief Business Strategy Officer
Mr. Johan M. Spoor	CEO & Director
Mr. Joel David Sendek	CFO & Principal Financial Officer
Mr. Chris Nenno	General Counsel & Corporate Secretary
Mr. Andrew Bright	Executive Vice President of Brachytherapy
Mr. Shane Cobb	Executive Vice President of Operations
Ms. Annie J. Cheng	Vice President of Investor Relations

FAQs

What is Perspective Therapeutics Inc. share price today?

Perspective Therapeutics Inc. share price today is $4.64 as on April 20, 2026 at 11:37 pm IST. Perspective Therapeutics Inc. share today touched a day high of $4.66 and a low of $4.31.

What is the 52 week high and 52 week low for Perspective Therapeutics Inc. share?

Perspective Therapeutics Inc. share touched a 52 week high of $6.16 on January 29, 2026 and a 52 week low of $1.86 on April 21, 2025. Perspective Therapeutics Inc. stock price today i.e. April 20, 2026 at 11:37 pm IST is trending at $4.64,which is 24.68% down from its 52 week high and 149.46% up from its 52 week low.

What is Perspective Therapeutics Inc.'s market capitalisation today?

Perspective Therapeutics Inc. market capitalisation is $0.00T as on April 20, 2026 at 11:37 pm IST.

How to invest in Perspective Therapeutics Inc. Stock (CATX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Perspective Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Perspective Therapeutics Inc. Shares that will get you 0.3233 shares as per Perspective Therapeutics Inc. share price of $4.64 per share as on April 20, 2026 at 11:37 pm IST.

What is the minimum amount required to buy Perspective Therapeutics Inc. Stock (CATX) from India?

Indian investors can start investing in Perspective Therapeutics Inc. (CATX) shares with as little as ₹93.107 or $1 (as of April 20, 2026 at 11:38 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹931.07 in Perspective Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on April 20, 2026 at 11:38 pm IST). Based on Perspective Therapeutics Inc. share’s latest price of $4.64 as on April 20, 2026 at 11:37 pm IST, you will get 2.1552 shares of Perspective Therapeutics Inc.. Learn more about fractional shares .